29,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

The objective of this study was analysing the role of S100A8 and S100A9 in the development of inflammatory skin diseases, in particular psoriasis. Both proteins are highly upregulated in the skin of psoriasis patients as well as in the mouse model for psoriasis caused by inducible, epidermal deletion of two AP 1 family members (JunB and c-Jun). Importantly, previous studies showed that S100A9-deficiency in the Jun/AP-1 psoriasis-like mouse model leads to loss of S100A8 and significantly reduces the severity of the inflammatory phenotype. The present study complements current findings and gives…mehr

Produktbeschreibung
The objective of this study was analysing the role of S100A8 and S100A9 in the development of inflammatory skin diseases, in particular psoriasis. Both proteins are highly upregulated in the skin of psoriasis patients as well as in the mouse model for psoriasis caused by inducible, epidermal deletion of two AP 1 family members (JunB and c-Jun). Importantly, previous studies showed that S100A9-deficiency in the Jun/AP-1 psoriasis-like mouse model leads to loss of S100A8 and significantly reduces the severity of the inflammatory phenotype. The present study complements current findings and gives insights into the cross talk between keratinocytes and immune cells, the main cell types involved in psoriasis. To this end, a detailed histological and molecular characterization of the skin and the cutaneous immune cell infiltrate of the Jun/AP-1 psoriasis-like mouse model upon S100A9 loss was performed. This analysis included determination of cytokine production in the dermis and epidermis as well as systemic mouse serum levels. Moreover, proliferation and cytokine secretion by cultured, S100A9-deficient keratinocytes of the Jun/AP-1 psoriasis-like mouse model was investigated. In summary, S100A8 and S100A9 appear to have a stimulating effect on psoriasis and inflammatory skin reactions.
Autorenporträt
Academic studies at the University of Vienna (Austria) with scientific stays at the Institute for Research in Immunology and Cancer (IRIC) Montréal, Canada and at the Spanish National Cancer Research Centre (CNIO) Madrid, Spain. PhD student at the London Research Institute (LRI) of Cancer Research UK, United Kingdom.